The price of OraSure Technologies Inc. (NASDAQ:OSUR) shares last traded on Wall Street fell -1.17% to $5.08.
Based on available information, 6 analysts follow OraSure Technologies Inc. (NASDAQ:OSUR). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $4.75, we find $5.00. Given the previous closing price of $5.14, this indicates a potential downside of -2.72 percent. OSUR stock price is now 1.78% away from the 50-day moving average and 15.73% away from the 200-day moving average. The market capitalization of the company currently stands at $367.44M.
Among analysts, 5 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $5.44 as their price target over the next twelve months.
, while ‘Evercore ISI’ rates the stock as ‘Outperform’.
In other news, LANCASTER RONNY B, Director bought 50,000 shares of the company’s stock on Aug 26. The stock was bought for $200,000 at an average price of $4.00. Upon completion of the transaction, the Director now directly owns 104,782 shares in the company, valued at $0.53 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 25, Director Aspinall Mara G. bought 6,000 shares of the business’s stock. A total of $25,138 was incurred on buying the stock at an average price of $4.19. This leaves the insider owning 77,218 shares of the company worth $0.39 million. Insiders disposed of 126,409 shares of company stock worth roughly $0.64 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OSUR stock. A new stake in OraSure Technologies Inc. shares was purchased by KENT LAKE CAPITAL LLC during the first quarter worth $6,424,000. SOLEUS CAPITAL MANAGEMENT, L.P. invested $2,870,000 in shares of OSUR during the first quarter. In the first quarter, CAXTON ASSOCIATES LP acquired a new stake in OraSure Technologies Inc. valued at approximately $782,000. GREAT WEST LIFE ASSURANCE CO /CAN/ acquired a new stake in OSUR for approximately $459,000. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. purchased a new stake in OSUR valued at around $404,000 in the second quarter. In total, there are 259 active investors with 87.90% ownership of the company’s stock.
A candlestick chart of OraSure Technologies Inc. (NASDAQ: OSUR) showed a price of $5.08 on Tuesday morning. During the past 12 months, OraSure Technologies Inc. has had a low of $2.62 and a high of $9.42. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 3.90, and a quick ratio of 2.80. The fifty day moving average price for OSUR is $4.99 and a two-hundred day moving average price translates $4.39 for the stock.
The latest earnings results from OraSure Technologies Inc. (NASDAQ: OSUR) was released for Jun, 2022. According to the Medical Instruments & Supplies Company, earnings per share came in at -$0.26, missing analysts’ expectations of -$0.13 by -0.13. This compares to -$0.21 EPS in the same period last year. The net profit margin was -13.40% and return on equity was -12.30% for OSUR. The company reported revenue of $116.46 million for the quarter, compared to $53.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 116.0 percent. For the current quarter, analysts expect OSUR to generate $91.71M in revenue.
OraSure Technologies Inc.(OSUR) Company Profile
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company’s principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.